Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1797083 | 0.83 | HTT (0.56) | HTTFGFR1TDP1MAPTALDH1A1 | |
| SCHEMBL5868998 | 0.82 | MAPK13 (0.57) | CYP1A2CYP2D6CYP2C19FGFR1MAPT | |
| SCHEMBL1757226 | 0.82 | PDE4A (0.59) | PDE4APDE4BPDE4CPDE4DCYP1A2 | |
| SCHEMBL8295724 | 0.82 | PDE4A (0.59) | PDE4APDE4BPDE4CPDE4DCYP1A2 | |
| SCHEMBL13784857 | 0.81 | CYP3A4 (0.50) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3712352 | 0.81 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DCYP1A2 | |
| SCHEMBL6626390 | 0.81 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DCYP1A2 | |
| SCHEMBL20678082 | 0.81 | HTT (0.54) | HTTFGFR1TDP1MAPTALDH1A1 | |
| SCHEMBL27985278 | 0.79 | CYP1A2 (0.65) | PDE4APDE4BPDE4CPDE4DCYP1A2 | |
| SCHEMBL1798351 | 0.79 | HTR2A (0.63) | HTTFGFR1MAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034718-B2 | C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2021-06-15 | — | — | US | disclosed |
| US-11034718-B2 | C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2021-06-15 | — | — | US | disclosed |
| US-20200087342-A1 | C-3 NOVEL TRITERPENONE WITH C-17 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LTD (IN) | 2020-03-19 | — | — | US | disclosed |
| US-20200087342-A1 | C-3 NOVEL TRITERPENONE WITH C-17 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LTD (IN) | 2020-03-19 | — | — | US | disclosed |
| US-20180215780-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | DFH THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215780-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | DFH THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215780-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | DFH THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| EP-3256483-A2 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | Hetero Labs Limited (IN) | 2017-12-20 | — | — | EP | disclosed |
| US-20170008921-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-01-12 | — | — | US | disclosed |
| US-20170008921-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-01-12 | — | — | US | disclosed |
| US-7592453-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-22 | — | — | US | disclosed |
| US-7592453-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-22 | — | — | US | disclosed |
| EP-2080760-A1 | Fused quinoline derivative and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2009-07-22 | — | — | EP | disclosed |
| EP-1740584-B1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2008-12-03 | — | — | EP | disclosed |
| EP-1740584-B1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2008-12-03 | — | — | EP | disclosed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1740584-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105802-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034718-B2 | C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors | IL17A, CDK17, CCR3 | HTT 3978/4885PDE4A 1769/4885PDE4B 2007/4885 |
| US-20200087342-A1 | C-3 NOVEL TRITERPENONE WITH C-17 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | IL17A, CDK17, CCR3 | HTT 3978/4885PDE4A 1769/4885PDE4B 2007/4885 |
| US-20170008921-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | ERG28, CCR3, ACBD3 | HTT 3936/4885PDE4A 1626/4885PDE4B 2606/4885 |
| US-20180215780-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | ERG28, CCR3, ACBD3 | HTT 4263/4885PDE4A 1681/4885PDE4B 2582/4885 |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TACR2, HRH3, HRH2 | HTT 3444/4885PDE4A 3730/4885PDE4B 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.